You are on Trendlyne United States. Click here to go to India website or make United States as your default
  1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : BIOTECHNOLOGY
  4. BIO-TECHNE CORP

Bio-Techne Corp XNAS: TECH

Bio-Techne Corp Live Share Price Today, Share Analysis and Chart

Expensive Underperformer
Download real time

48.10 -1.88 (-3.76%)

Near 52W Low of $46.44

2.7M XNAS Volume

XNAS 17 Apr, 2025 5:30 PM (EDT)

Watchlist

Portfolio

Share
Board Meeting
The next board meeting for Bio-Techne Corp is on 01 May 2025 for the purpose of Bio-Techne Corp Third Quarter Earnings Conference Call for 2025 See details

Bio-Techne Corp Key Metrics

Default

Market Capitalization

High in industry
7,604

PE TTM

High in industry
48.1

PEG TTM

Negative PEG TTM
-1.6

Price to Book

Below industry Median
3.7

Institutional holding current Qtr %

High in industry
101.2

Revenue Growth Qtr YoY %

Below industry Median
9

Operating Revenue growth TTM %

Below industry Median
4.5

Net Profit Qtr Growth YoY %

Below industry Median
27

Net Profit TTM Growth %

Negative Net Profit TTM Growth %
-29.5

Operating Profit Margin Qtr %

High in industry
16

Operating Profit Margin TTM %

High in industry
19.8

Piotroski Score

High in industry
5

Rel Perf vs Sector quarter%

-35.6

ROE Annual %

High in industry
8.3

RoA Annual %

High in industry
6.3
All financials are in USD Million and price data in USD
VIEW MORE
Durability score
Medium Financial Strength
44.4 / 100
Valuation Score
Expensive Valuation
24.2 / 100
Momentum Score
Technically Bearish
26.1 / 100
Expensive Underperformer These stocks are medium in financial scores. They have bad valuation and technical scores as well. View Similar Embed DVM
Analyst Price Target
80
1Yr Price target upside is 66%
12 analysts

6

S

17

W

5

O

1

T

SWOT Analysis

Bio-Techne Corp Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2Jun '22Jun '23Jun '24Jun '25Jun '2610001200140011001300Actual RevenueAvg. Estimate
Miss

Bio-Techne Corp's Revenue was lower than average estimate 3 times in past 3 years

EPS forecast

Current EPS
1.1
Avg. Estimate
1.2
Low Estimate
1
High Estimate
1.4
Current EPS
Avg. Estimate
Hit

EPS is expected to grow by 10.5% in FY25

Consensus Recommendation

15 ANALYST Recommendations
BUY

Created with Highcharts 7.2.25Hold2Buy8Strong Buy

The consensus recommendation from 15 analysts for Bio-Techne Corp is BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Bio-Techne Corp Stock Analysis

Bio-Techne Corp stock analysis with key metrics, changes, and trends.

Bio-Techne Corp MetricVALUECHANGE %TRENDANALYSIS
Annual Revenue$1,159.06 M1.97%positive

Annual Revenue rose 1.97%, in the last year to $1,159.06 M. Its sector's average revenue growth for the last fiscal year was 7.54%.

Annual Net Profit$168.1 M41.07%negative

Annual Net Profit fell 41.07% in the last year to $168.1 M. Its sector's average net profit growth for the last fiscal year was -30.36%.

Price to Earning Ratio48.09-negative

Price to Earning Ratio is 48.09, higher than its sector PE ratio of 3.22.

Stock Price$48.10-22.57%negative

Stock Price fell 22.57% and underperformed its sector by 29.9% in the past year.

Quarterly Revenue$297.03 M8.96%positive

Quarterly Revenue rose 8.96% YoY to $297.03 M. Its sector's average revenue growth YoY for the quarter was 5.84%.

Quarterly Net profit$34.89 M27.03%positive

Quarterly Net profit rose 27.03% YoY to $34.89 M. Its sector's average net profit growth YoY for the quarter was -48.37%.

Debt to Equity Ratio0.2-positive

Debt to Equity Ratio of 0.2 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE)8.33 %8.33%negative

Return on Equity(ROE) for the last financial year was 8.33%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding92.68 %0.48%positive

Mutual Fund Holding increased by 0.48% in the last quarter to 92.68.

Promoter Share Holding0.93 %0.02%positive

Promoter Share Holding increased by 0.02% in the most recent quarter to 0.93%.

Interest Coverage Ratio12.8-positive

Interest Coverage Ratio is 12.8, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).

Institutional Holding101.16 %0.14%positive

Institutional Holding increased by 0.14% in the last quarter to 101.16.

VIEW LESS


Loading data..

Bio-Techne Corp - Company Profile

What does Bio-Techne Corp do?

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Bio-Techne Corp Management structure

All Gross Remunerations are in USD
Mr. Kim Kelderman
President, Chief Executive Officer and Director
6.85 M
2024
Gross Remuneration
Year
Mr. Charles R. Kummeth
Director, President and Chief Executive Officer
6.79 M
2024
Gross Remuneration
Year
Mr. James T. Hippel
Principal Accounting Officer, Executive Vice President and Chief Financial Officer
5.2 M
2024
Gross Remuneration
Year
Mr. William Geist
President, Protein Sciences
3.65 M
2024
Gross Remuneration
Year
Dr. Matthew McManus
President, Diagnostics and Genomics Segment
1.99 M
2024
Gross Remuneration
Year
Mr. Shane Bohnen
Senior Vice President, General Counsel and Corporate Secretary
1.46 M
2024
Gross Remuneration
Year

Bio-Techne Corp Board of directors

All Gross Remunerations are in USD
Dr. Roeland Nusse,PhD
Independent Director
-
2025
Gross Remuneration
Year
Dr. Amy Herr, PhD
Independent Director
-
2025
Gross Remuneration
Year

Bio-Techne Corp FAQ

How is Bio-Techne Corp today?
Bio-Techne Corp today is trading in the red, and is down by -3.76% at 48.10.
Bio-Techne Corp is currently trading down -3.76% on an intraday basis. In the past week the stock fell -5.17%. stock has been down -36.57% in the past quarter and fell -22.57% in the past year. You can view this in the overview section.